<DOC>
	<DOCNO>NCT01825889</DOCNO>
	<brief_summary>The purpose study measure much study drug , evacetrapib , get blood stream long take body get rid give participant severe renal ( kidney ) impairment compare participant normal renal ( kidney ) function . This study last approximately 8 week .</brief_summary>
	<brief_title>A Study Evacetrapib ( LY2484595 ) Participants With Kidney Impairment Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Evacetrapib</mesh_term>
	<criteria>Female participant childbearing potential Have body mass index 18 40 kilogram per square meter ( kg/m^2 ) Participants normal renal function healthy determine medical history , physical examination , screen procedure , normal renal function ( assess estimate creatinine clearance [ CLcr ] great equal 90 milliliter per minute [ mL/min ] screening ) Participants severe renal impairment estimate CLcr le 30 mL/min screen undergoing hemodialysis Have history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data . Participants unwilling comply dietary requirements/restrictions study Hemoglobin le 9 grams/deciliter ( g/dL ) significant active hematological disease cause underlying renal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>